US equities
|
MU
$1,044.70
▼-1.92%
NVDA
$229.32
▲+0.41%
SNDK
$1,732.27
▼-0.44%
INTC
$120.11
▼-0.10%
AMD
$610.00
▼-0.29%
TSLA
$359.12
▲+1.21%
GOOGL
$340.86
▼-0.94%
LITE
$1,061.98
▲+9.34%
MU
$1,044.70
▼-1.92%
NVDA
$229.32
▲+0.41%
SNDK
$1,732.27
▼-0.44%
INTC
$120.11
▼-0.10%
AMD
$610.00
▼-0.29%
TSLA
$359.12
▲+1.21%
GOOGL
$340.86
▼-0.94%
LITE
$1,061.98
▲+9.34%
FinancialContent
Watchlist
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
My watchlist
My portfolio
Recent quotes
Hikma Pharmaceuticals Plc.
(OP:
HKMPY
)
43.00
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Sep 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hikma Pharmaceuticals Plc.
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
March 26, 2026
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...
Via
MarketMinute
Topics
Intellectual Property
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
March 20, 2025
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada
From
Emergent BioSolutions
Via
GlobeNewswire
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
↗
September 06, 2024
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.
Via
Benzinga
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
↗
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
↗
June 12, 2023
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat...
Via
Benzinga
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
December 26, 2022
From
Junshi Biosciences
Via
GlobeNewswire
Friday Markets News
↗
March 25, 2022
Methane leaks in the Permian Basin are 6 times higher than estimates.
Via
Talk Markets
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
August 27, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Summer Friday
↗
June 25, 2021
The stock market tried for another record after yesterday's late blowout over the infrastructure deal.
Via
Talk Markets
